TY  - GEN
AU  - Adjei,Alex A
AU  - Richards,Donald A
AU  - El-Khoueiry,Anthony
AU  - Braiteh,Fadi
AU  - Becerra,Carlos H R
AU  - Stephenson,Joe J
AU  - Hezel,Aram F
AU  - Sherman,Morris
AU  - Garbo,Lawrence
AU  - Leffingwell,Diane P
AU  - Iverson,Cory
AU  - Miner,Jeffrey N
AU  - Shen,Zancong
AU  - Yeh,Li-Tain
AU  - Gunawan,Sonny
AU  - Wilson,David M
AU  - Manhard,Kimberly J
AU  - Rajagopalan,Prabhu
AU  - Krissel,Heiko
AU  - Clendeninn,Neil J
TI  - A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
SN  - 1557-3265
PY  - 2018///0108
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Combined Modality Therapy
KW  - methods
KW  - Diphenylamine
KW  - Female
KW  - Half-Life
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasms
KW  - blood
KW  - Niacinamide
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Sorafenib
KW  - Sulfonamides
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1158/1078-0432.CCR-15-1681
ER  -